Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

ope.

UVIDEM has been administered to 143 patients in clinical development. Patient enrollment has been completed in three other Phase 2 clinical trials including individuals with resected stage 2 or 3 melanoma and individuals with metastatic melanoma. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma.

IDM-2101

The Company announced updated results in November 2007 from its Phase 2 trial in patients with non-small cell lung cancer (NSCLC) who were vaccinated with IDM-2101, compared to a parallel external control group of non-vaccinated patients. Updated one-year survival in patients treated with IDM-2101 was 60 percent, compared to 49 percent in a group of seventy-two patients who were HLA-A2 negative but otherwise comparable (external comparator group). Median survival for patients treated with IDM-2101 was 17.3 months compared to 12.0 months for patients in the comparator group.

Based on this encouraging survival trend, the Company has continued to work with outside consultants and clinical advisors to develop a next-step clinical plan for IDM-2101. The Company expects to have the clinical plan completed by the end of 2007.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

At September 30, 2007 the Company had cash and cash equivalents of $33.2 million.

For more information about the Company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release and the presentation described in this press release include forward
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... , Sept. 14, 2014 /PRNewswire-iReach/ -- "Hematoma Global Clinical ... clinical trial scenario. This report provides elemental information and ... includes an overview of the trial numbers and their ... across the globe. The databook offers a preliminary coverage ... prominence of the sponsors and also provides briefing pertaining ...
(Date:9/14/2014)... , September 14, 2014 Elbit ... EMITF ) announced today further to the Company,s ... (the "Company,s Previous Reports"), that it was informed by ... US$ 12.5 million by  Shanghai GEOC Hengtong Investment Limited ... the framework of the present investment round in InSightec, ...
(Date:9/12/2014)... 2014 In the current outcomes-focused market, ... Health Outcomes Liaison (HOL) staff to serve as ... and other important healthcare decision makers. As the ... successful companies will need to understand how to ... To help organizations identify industry trends ...
Breaking Medicine Technology:Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 2Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 3Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 4Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 5Elbit Imaging Ltd. Announces Investment of US$ 12.5 Million in Insightec by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited 2Elbit Imaging Ltd. Announces Investment of US$ 12.5 Million in Insightec by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited 3Pharmaceutical Sector Turning to Health Outcomes Liaisons to Help Industry Navigate Payer-Focused Marketplace 2
(Date:9/14/2014)... 14, 2014 Adults who are planning ... Quotes Pros website to find quotes for life insurance ... year at http://quotespros.com/life-insurance.html is now delivering the ... partners that are preparing the rates information for adults ... most U.S. states. As a way to simplify the ...
(Date:9/14/2014)... York, New York (PRWEB) September 14, 2014 ... ) continue to move forward in courts throughout ... a brief filed in San Francisco Superior Court, ... have asked the judge overseeing the proceeding to ... their cases re-transferred to Los Angeles Superior Court. ...
(Date:9/14/2014)... Top10BestSEOHosting.com always offers truly reliable information ... suppliers carefully, the site has announced that Arvixe ... Best WordPress Hosting suppliers in the current market. ... web hosting provider, and the company’s reputation for ... provider known for its flexible hosting packages, decent ...
(Date:9/14/2014)... 14, 2014 School requires that children read ... that they be screened only for far vision when they ... away. When their eyes do not track effectively or ... will, at best, avoid reading; at worst, they will ... ability to learn. Children who cannot see cannot read. ...
(Date:9/13/2014)... PA (PRWEB) September 13, 2014 “I ... air we breathe, especially in major cities, is quite ... Ancaster, Ontario, Canada. “I thought we deserved a healthier ... they invented THE OXYGENIZER. , THE OXYGENIZER prevents pollutants ... and mouth. In doing so, it provides added peace ...
Breaking Medicine News(10 mins):Health News:Quotes for Life Insurance Now Offered at New Consumer Portal Online 2Health News:DePuy ASR Lawsuit News: Defense Asks Judge Overseeing California Litigation to Deny Opt-Out Plaintiffs’ Re-Transfer Request, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Lawsuit News: Defense Asks Judge Overseeing California Litigation to Deny Opt-Out Plaintiffs’ Re-Transfer Request, Bernstein Liebhard LLP Reports 3Health News:DePuy ASR Lawsuit News: Defense Asks Judge Overseeing California Litigation to Deny Opt-Out Plaintiffs’ Re-Transfer Request, Bernstein Liebhard LLP Reports 4Health News:Top10BestSEOHosting.com: The Best Linux Web Hosting Suppliers Now Unveiled 2Health News:Personal Air Filtering Device Invented by InventHelp Clients (TOR-9166) 2
... Nov. 11 Ken Herron, Chief Marketing,Executive at ... announced,today that David S. Novak of the Centers ... team at Online Buddies, Inc. as the site,s ... networking site for,gay men, with 2,000,000 members worldwide, ...
... - Global Health,innovator IntraHealth International will participate as ... to improve public health needs in the,West Bank, ... to Washington,DC-based Chemonics International and its subcontractors by ... The new Palestinian Health Sector Reform Project aims ...
... In women, habitual snoring may be an independent ... regardless of sleep apnea occurrences. Researchers from Sweden ... aged 20 to 70 years. The apnea-hypopnea index ... loudly and disturbingly often or very often were ...
... Germany, Nov. 11 Texas Instruments,(NYSE: ... of more than 15 dedicated,embedded processors which ... clinicians while empowering imaging equipment manufacturers to ... smaller and more portable.,These processors target several ...
... his speech today at electronica 2008, Pat O’Doherty, ... spotlighted how sophisticated healthcare semiconductor technology is paving ... and more powerful medical devices for use in ... of devices include those that check glucose levels ...
... 85 Americans die by suicide and hundreds of thousands more ... on suicide have focused on identifying psychiatric risk factors. However, ... published online this month in Social Science and Medicine ... closely analyzing the patterns of suicide in a single geographic ...
Cached Medicine News:Health News:MANHUNT Leads Fight Against Spread of Sexually Transmitted Infections with Launch of MANHUNT Cares; Hires Senior Public Health Strategist from CDC 2Health News:IntraHealth to Support Health Reform in Palestine 2Health News:Journal CHEST: Nov. highlights 2Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 2Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 3Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 4Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 5Health News: Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008. 2Health News: Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008. 3Health News:What happens in Vegas? Place as a risk factor for suicide 2
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of digoxin in human serum or plasma. Emit 2000 assays are designed for use with most chem...
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
... (Rapid Plasma Reagin) 18-mm Circle Card ... testing procedures for the serological detection ... of Tests for Syphilis.* The test ... most widely used in the United ...
... a non-reactive quality assurance reagent in assays detecting ... IgG and TOXO IgM), IgG and IgM antibodies ... IgG and IgM antibodies to cytomegalovirus (CMV IgG ... herpes simplex virus types 1 and 2 (HSV-1 ...
Medicine Products: